Arjun Goyal, M.D., M.PHIL., M.B.A.
Dr. Arjun Goyal is a Co-Founder and Managing Director of Vida Ventures, a leading US-based life sciences venture capital firm with approximately $1.7 billion in AUM. Arjun focuses on creating…
Dr. Arjun Goyal is a Co-Founder and Managing Director of Vida Ventures, a leading US-based life sciences venture capital firm with approximately $1.7 billion in AUM. Arjun focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Arjun serves as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, Affini-T, Alterome Therapeutics and Centessa Pharmaceuticals and has played key roles in Vida Venture’s investments in Homology Medicines, Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer).
Before co-founding Vida Ventures in 2017, Arjun was a life sciences investor at 5AM Ventures. Arjun received his B.Sc. in Medical Science, Diploma in French and his MBBS degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his M.Phil. in Bioscience Enterprise from University of Cambridge and his MBA from Harvard Business School. Arjun has received multiple awards for his work including the Advance Award for Technology & Entrepreneurship from the Australian Government. He is a co-inventor on one patent and had served on the editorial board of an international scientific journal. He serves on the Committee for the American Australian Association Education Fellowship.